Halter raises $100 million to make smart cow collars
Why it matters: The round is designed to further enable U.S. expansion, at a time when many cattle ranches are facing labor shortages due to increased immigration enforcement.
Other investors include NewView, Bessemer Venture Partners, DCVC, Blackbird, Icehouse Ventures, and Promus Ventures.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Asia Morning Briefing: BTC Smashes Through All-Time High With No Sell Pressure on the Horizon
Welcome to Asia Morning Briefing, a daily summary of top stories during U.S. hours and an overview of market moves and analysis. For a detailed overview of U.S. markets, see CoinDesk's Crypto Daybook trading day is starting with a bang as bitcoin (BTC) breached its all-time high during the U.S. trading day, and is currently changing hands above $115,300, according to CoinDesk market data. Bitcoin has experienced its share of rallies before, but on-chain data indicates that this time, things are different. Usually, when BTC has a rapid price appreciation, selling pressure increases accordingly. A new CryptoQuant report, however, shows that its HODLing season. 'Bitcoin selling pressure remains low despite the price reaching a fresh all-time high of $112.2K yesterday,' the firm wrote, adding that 'a declining amount of Bitcoin flowing into exchanges indicates less selling pressure from new capital flows.' BTC exchange inflows have dropped to just 18,000 BTC per day, the lowest level since April 2015. That lack of sell pressure isn't just limited to retail-sized wallets. The report shows that large holders, wallets sending 100 or more BTC, have also pulled back sharply. 'The daily amount of Bitcoin sent to exchanges in batches of 100 or more BTC has declined from 62K Bitcoin on November 26, 2024, to 7K BTC today,' CryptoQuant wrote. Other major tokens show a similar trend. Ethereum (ETH) inflows are down from 1.57 million ETH in February to just 584,000, a drop that coincided with an 87% rally since April. Meanwhile, XRP whales have 'remained on the sidelines,' with daily inflows falling 85% from 1.1 billion XRP in February to 169 million today. Even smaller altcoins reflect the same behavior. Daily altcoin inflow transactions, a proxy for broad retail activity, are just 21,000, compared to 120,000 during market tops in March and December 2024. The report notes this reinforces 'the prevailing low-pressure environment.' For now, the data shows this is not a typical top. It's a breakout with no rush to exit. HODLing season. Bitcoin (BTC) is now the sixth most valuable asset in the world, trading at $115,595 with a market capitalization of $2.298 trillion, having overtaken Alphabet (Google) and inching closer to Amazon at $2.359 trillion. This milestone marks a return to territory BTC briefly held in May, when it surpassed Amazon with a $2.16 trillion valuation after rallying to a then-record high of $109,400. Though the market briefly consolidated lower, recent strength, driven by macro tailwinds and institutional demand, has pushed bitcoin even higher, rewriting the leaderboard once again. One key driver behind this resurgence: spot bitcoin ETFs. After net outflows in February and March totaling over $4.3 billion, the market has rebounded strongly. May saw $5.23 billion in net inflows, followed by $4.6 billion in June and $1.18 billion so far in July. Cumulative net inflows now exceed $50 billion, according to SoSoValue. With total ETF net assets approaching $140 billion, this institutional presence is no longer just a narrative, it's reshaping market structure. The next psychological milestone? A clean flip of Amazon and a potential march toward Apple ($3.17T) and Microsoft ($3.72T). BTC: Bitcoin surged past $116,000 on Thursday, setting a new all-time high and nearly doubling over the past year, while triggering $950 million in short liquidations, the largest single-day wipeout of bearish bets in 2025, according to CoinGlass. ETH: Ethereum's ETH surged to nearly $3,000, its highest in over four months, as strong ETF inflows, growing adoption in tokenization and corporate treasuries, with shifting market sentiment fueling a strong rally. Gold: Gold is down about 4% from its June 13 high of $3,432.56, recently trading around $3,294.71, marking a modest pullback that some investors see as a buying opportunity amid forecasts that the metal could climb to $4,000 sooner than expected. Nikkei 225: Asia-Pacific markets traded mixed Friday after President Trump announced 35% tariffs on Canada and signaled plans for broad 15–20% tariffs on most U.S. trade partners. S&P 500: U.S. stocks closed at fresh record highs Thursday as Nvidia edged up and bitcoin surged, with the S&P 500 hitting 6,280.46 and the Nasdaq logging a second consecutive all-time high despite renewed tariff threats from President Trump. Former Bitfury Exec Gould Confirmed to Take Over U.S. Banking Agency OCC (CoinDesk) Securities On-Chain? There's Only One True Way, Says BlackRock-Backed Firm's CEO (Decrypt) MARA Holdings Names Ex-Blue River Exec as CPO to Lead Productization of Energy Tech (CoinDesk) Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
an hour ago
- Yahoo
Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ...
Net Sales: SEK178 million in Q2, with an organic growth of -11%. Gross Margin: Stable at 74% for both Q2 and year-to-date. Adjusted EBITDA: 13% for the quarter. Thoracic Sales: SEK105 million in Q2, with an organic growth of -19%. Lung Sales: Negative growth of -10% in local currencies; however, outside the largest US customer, lung sales grew by 26%. Heart Sales: SEK3 million in Q2, compared to SEK19 million last year. Abdominal Sales: SEK52 million, with an organic growth of 19%. Liver Sales Growth: 28% in local currencies, with 32% growth in main European markets. Kidney Sales: Declined by 2%, but US Kidney Assist Transport disposables grew by 47%. Services Sales: SEK21 million, with organ recovery part decreasing by 19%. Operating Cash Flow: Positive SEK9 million in Q2. Investments: SEK72 million, primarily for US clinical trials and perfusion devices. Release Date: July 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Xvivo Perfusion AB (XVIPF) reported strong growth in specific segments, with US lung sales to clinics and OPOs growing by 26%, liver sales in Europe increasing by 32%, and kidney sales in the US rising by 47% during the second quarter. The company achieved significant milestones for future growth, including a 76% risk reduction in severe PGD from the European Heart Study, which led to improved patient survival. There is a high interest in starting EVLP programs, with four new XPS customers in the US in the first six months of 2025, indicating potential for future growth. Xvivo Perfusion AB (XVIPF) maintained a stable gross margin of 74% despite currency headwinds, demonstrating resilience in its business model. The company is preparing for the launch of heart products in Europe and has seen high interest from clinics, indicating potential for future revenue growth in this segment. Xvivo Perfusion AB (XVIPF) reported negative top-line growth in Q2 2025 compared to the same quarter last year, primarily due to a slower-than-expected lung market, lack of heart sales, and a weaker US dollar. The company's EBITDA as a percentage of sales decreased this quarter, reflecting challenges in maintaining profitability amidst sales declines. There was a significant destocking issue with the largest US lung customer, impacting sales negatively by approximately USD 1.5 million. Heart sales were significantly lower in Q2 2025 compared to last year, with only SEK3 million in sales versus SEK19 million last year, due to the absence of trial revenue. The US service business progress was unsatisfactory, with a strategic review indicating a need for improvement in this area. Q: Can you provide more details on the destocking issue with your largest lung customer and when it might end? A: The destocking was unexpected due to slower growth in the EVLP market. It will likely stop when the market returns to normal growth levels. If the market stabilizes, we don't expect further inventory reductions. The impact in Q2 was approximately USD 1.5 million. Christoffer Rosenblad, CEO Q: With new EVLP centers ramping up in the US, do you expect growth from direct US lung customers to accelerate? A: We aim to accelerate growth by investing in customer-facing personnel to ramp up new accounts. We are planning for a better second half compared to the first half. Christoffer Rosenblad, CEO Q: What is the expected sales contribution from heart products in Europe if approval is received in Q3? A: Sales will ramp up gradually as we list the product country by country and activate clinics. We expect increasing sales quarter-on-quarter rather than a high initial launch volume. Christoffer Rosenblad, CEO Q: What is the status of the liver trial and the continuous access protocol for heart in the US? A: The first patient for the heart protocol could be any day, depending on waitlist matching. For the liver trial, we aim to include the first patient by the end of Q3. Christoffer Rosenblad, CEO Q: How is the interest from OPOs affecting your strategy, and what is the timeline for supporting them? A: We see OPOs as a crucial customer group due to the NRP trend. We have some homework to do to best cooperate with them, but we expect to be ready to support them in less than 12 months. Christoffer Rosenblad, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
US D-9 bulldozers worth billions of shekels arrive in Israel after Trump admin. releases shipment
Over 100,000 tons of military equipment have arrived in Israel through 870 airlifts and 144 sea shipments since the start of the war. A US shipment of dozens of D-9 bulldozers for IDF ground troops arrived in Israel on Wednesday, following its release by the Trump administration, the Defense Ministry confirmed. "The shipment of D9 bulldozers is part of a broad-scale arming and military equipment effort worth billions of shekels, which the US government released and the Defense Ministry procured and transported to Israel," Defense Ministry Director-General Maj.-Gen. (res) Amir Baram said, adding that Israel has received a number of cargo ships and aircrafts in the past several weeks. "We must continue to strengthen our military buildup to support all of the IDF's needs in the current campaign and in preparation for the next decade," Baram said. Over 100,000 tons of military equipment have arrived in Israel through 870 airlifts and 144 sea shipments since the start of the war. According to the ministry, this is the largest exchange in Israel's history. The shipment was conducted in a joint operation led by the Defense Ministry's procurement delegation in the US, the IDF Planning Directorate, and the International Security Transport Unit within the ministry.
